Stock XSPRAY XSPRAY PHARMA AB
Add to a list
To use this feature you must be a member
Log inSign up

Financials Xspray Pharma AB

Equities

XSPRAY

SE0009973563

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm
Other stock markets
 12:00:00 2024-06-28 EDT 		5-day change 1st Jan Change
80.4 SEK +0.12% Intraday chart for Xspray Pharma AB +4.15% +101.00%
05-23 Xspray Pharma AB Announces to Present Data At ASCO Highlighting Frequent Decideication of PPIs with TKIs in CML-Patients and Greater Than Expected Positive Effects on the Bioavailability of Crystalline Dasatinib CI
05-20 Xspray Pharma AB Appoints Linda Glimberg as Chief Operating Officer, Effective June 1, 2024 CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 1,394 3,665 1,326 1,293 1,250 2,714 - -
Enterprise Value (EV) 1 1,184 3,665 1,057 1,175 1,121 2,453 2,714 2,714
P/E ratio -27.6 x -63.6 x -12.7 x -9.12 x -5.92 x 3.75 x - -
Yield - - - - - 1.24% - -
Capitalization / Revenue - - - - - 3.81 x 3.44 x 1.69 x
EV / Revenue - - - - - 3.44 x 3.44 x 1.69 x
EV / EBITDA -28.3 x - -11.9 x -9.51 x -6.49 x -8.82 x 11.7 x 2.75 x
EV / FCF -9.38 x - -20 x - -5.44 x -6.42 x 30.2 x -
FCF Yield -10.7% - -5.01% - -18.4% -15.6% 3.32% -
Price to Book - - 2.24 x 2.33 x 1.53 x 1.33 x - -
Nbr of stocks (in thousands) 16,752 18,893 20,680 22,680 31,254 33,762 - -
Reference price 2 83.20 194.0 64.10 57.00 40.00 80.40 80.40 80.40
Announcement Date 20-02-28 21-02-25 22-02-18 23-02-15 24-02-14 - - -
1SEK in Million2SEK
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 - - - - - 713.4 789 1,605
EBITDA 1 -41.76 - -89.08 -123.5 -172.5 -278 233 986
EBIT 1 -46.56 - -97.95 -133.1 -181.7 -293 214 946
Operating Margin - - - - - -41.07% 27.12% 58.94%
Earnings before Tax (EBT) 1 -45.77 - -96.7 -131.7 -179.7 754.4 - -
Net income 1 -45.77 -52.41 -96.7 -131.7 -179.7 596 - -
Net margin - - - - - 83.55% - -
EPS 2 -3.010 -3.050 -5.030 -6.250 -6.760 21.42 - -
Free Cash Flow 1 -126.2 - -52.92 - -206 -382 90 -
FCF margin - - - - - -53.55% 11.41% -
FCF Conversion (EBITDA) - - - - - - 38.63% -
FCF Conversion (Net income) - - - - - - - -
Dividend per Share 2 - - - - - 1.000 - -
Announcement Date 20-02-28 21-02-25 22-02-18 23-02-15 24-02-14 - - -
1SEK in Million2SEK
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4
Net sales - - - - -
EBITDA 1 -49.98 -16.96 -26.82 -26.6 -53.16
EBIT 1 -52.28 -19.28 -29.21 -28.99 -55.59
Operating Margin - - - - -
Earnings before Tax (EBT) 1 -51.94 -18.93 -28.86 -28.65 -55.22
Net income 1 -51.94 -18.93 -28.86 -28.65 -55.22
Net margin - - - - -
EPS 2 -2.620 -0.9200 -1.400 -1.390 -2.480
Dividend per Share - - - - -
Announcement Date 22-02-18 22-05-06 22-08-05 22-11-09 23-02-15
1SEK in Million2SEK
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 210 - 269 118 129 262 - -
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 -126 - -52.9 - -206 -382 90 -
ROE (net income / shareholders' equity) -13.5% - - - - 55% - -
ROA (Net income/ Total Assets) - - - - - - - -
Assets 1 - - - - - - - -
Book Value Per Share 2 - - 28.60 24.50 26.10 60.40 - -
Cash Flow per Share - - - - - - - -
Capex 1 23.1 - 1.31 - 2.69 26 28 -
Capex / Sales - - - - - 3.64% 3.55% -
Announcement Date 20-02-28 21-02-25 22-02-18 23-02-15 24-02-14 - - -
1SEK in Million2SEK
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
80.4 SEK
Average target price
107 SEK
Spread / Average Target
+33.08%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
XSPRAY PHARMA AB Stock Xspray Pharma AB
+101.00% 256M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+15.20% 121B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+19.67% 113B
ARGENX SE Stock argenx SE
+18.95% 26.02B
BIONTECH SE Stock BioNTech SE
-23.86% 19.39B
GENMAB A/S Stock Genmab A/S
-19.03% 15.91B
BEIGENE, LTD. Stock BeiGene, Ltd.
-20.90% 15.09B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-46.14% 15.06B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+63.85% 14.93B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+4.49% 13.85B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. XSPRAY Stock
  4. Financials Xspray Pharma AB